Literature DB >> 28856736

Interactions between bile salts, gut microbiota, and hepatic innate immunity.

Kristin Schubert1, Steven W M Olde Damink2,3, Martin von Bergen1,4, Frank G Schaap2,3.   

Abstract

Bile salts are the water-soluble end products of hepatic cholesterol catabolism that are released into the duodenum and solubilize lipids due to their amphipathic structure. Bile salts also act as endogenous ligands for dedicated nuclear receptors that exert a plethora of biological processes, mostly related to metabolism. Bile salts are actively reclaimed in the distal part of the small intestine, released into the portal system, and subsequently extracted by the liver. This enterohepatic cycle is critically dependent on dedicated bile salt transporters. In the intestinal lumen, bile salts exert direct antimicrobial activity based on their detergent property and shape the gut microbiota. Bile salt metabolism by gut microbiota serves as a mechanism to counteract this toxicity and generates bile salt species that are distinct from those of the host. Innate immune cells of the liver play an important role in the early recognition and effector response to invading microbes. Bile salts signal primarily via the membrane receptor TGR5 and the intracellular farnesoid-x receptor, both present in innate immune cells. In this review, the interactions between bile salts, gut microbiota, and hepatic innate immunity are discussed.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  FXR; bile salt metabolism; bile salt signaling; bile salt toxicity; innate immunity; microbiota:host interaction

Mesh:

Substances:

Year:  2017        PMID: 28856736     DOI: 10.1111/imr.12579

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  21 in total

Review 1.  Microbiome, bile acids, and obesity: How microbially modified metabolites shape anti-tumor immunity.

Authors:  Laura M Sipe; Mehdi Chaib; Ajeeth K Pingili; Joseph F Pierre; Liza Makowski
Journal:  Immunol Rev       Date:  2020-05       Impact factor: 12.988

2.  First Insight into the Probiotic Properties of Ten Streptococcus thermophilus Strains Based on In Vitro Conditions.

Authors:  Jie Zhang; Miaomiao Liu; Junnan Xu; Yiman Qi; Ning Zhao; Mingtao Fan
Journal:  Curr Microbiol       Date:  2019-12-12       Impact factor: 2.188

Review 3.  Low diversity gut microbiota dysbiosis: drivers, functional implications and recovery.

Authors:  Michael Kriss; Keith Z Hazleton; Nichole M Nusbacher; Casey G Martin; Catherine A Lozupone
Journal:  Curr Opin Microbiol       Date:  2018-07-20       Impact factor: 7.934

4.  Extreme Acid Modulates Fitness Trade-Offs of Multidrug Efflux Pumps MdtEF-TolC and AcrAB-TolC in Escherichia coli K-12.

Authors:  Samantha H Schaffner; Abigail V Lee; Minh T N Pham; Beimnet B Kassaye; Haofan Li; Sheetal Tallada; Cassandra Lis; Mark Lang; Yangyang Liu; Nafeez Ahmed; Logan G Galbraith; Jeremy P Moore; Katarina M Bischof; Chelsea C Menke; Joan L Slonczewski
Journal:  Appl Environ Microbiol       Date:  2021-07-27       Impact factor: 4.792

Review 5.  Managing portal hypertension in patients with liver cirrhosis.

Authors:  Tilman Sauerbruch; Robert Schierwagen; Jonel Trebicka
Journal:  F1000Res       Date:  2018-05-02

6.  Qualitative and Quantitative DNA- and RNA-Based Analysis of the Bacterial Stomach Microbiota in Humans, Mice, and Gerbils.

Authors:  Gregor Gorkiewicz; W Florian Fricke; Philipp Wurm; Elisabeth Dörner; Christina Kremer; Julia Spranger; Cynthia Maddox; Bettina Halwachs; Ute Harrison; Thomas Blanchard; Rainer Haas; Christoph Högenauer
Journal:  mSystems       Date:  2018-11-20       Impact factor: 6.496

Review 7.  Interplay Between the Host, the Human Microbiome, and Drug Metabolism.

Authors:  Robert G Nichols; Jeffrey M Peters; Andrew D Patterson
Journal:  Hum Genomics       Date:  2019-06-11       Impact factor: 4.639

Review 8.  Pathogenesis of Nonalcoholic Steatohepatitis: An Overview.

Authors:  Gopanandan Parthasarathy; Xavier Revelo; Harmeet Malhi
Journal:  Hepatol Commun       Date:  2020-01-14

9.  Farnesoid X Receptor Activation Protects Liver From Ischemia/Reperfusion Injury by Up-Regulating Small Heterodimer Partner in Kupffer Cells.

Authors:  Dan Jin; Tianfei Lu; Ming Ni; Han Wang; Jiang Zhang; Chenpeng Zhong; Chuan Shen; Jun Hao; Ronald W Busuttil; Jerzy W Kupiec-Weglinski; Jianjun Zhang; Ning Xu; Yuan Zhai
Journal:  Hepatol Commun       Date:  2020-02-13

10.  Clinical and microbiological characteristics of patients with biliary disease.

Authors:  Xue-Xiang Gu; Meng-Pei Zhang; Yan-Feng Zhao; Guang-Ming Huang
Journal:  World J Gastroenterol       Date:  2020-04-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.